There are currently 587 clinical trials in Richmond, Virginia looking for participants to engage in research studies. Trials are conducted at various facilities, including Virginia Commonwealth University, Virginia Commonwealth University/Massey Cancer Center, GSK Investigational Site and Virginia Cancer Institute. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia
NCT05384587
Recruiting
This will be a multicenter Phase II open-label study of asciminib in CML-CP patients who have been previously treated with one prior ATP- binding site TKI with discontinuation due to treatment failure, warning or intolerance. (2L patient cohort). In addition, newly diagnosed CML-CP patients who may have received up to 4 weeks of prior TKI are included in a separate 1L patient cohort.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/06/2024
Locations: Virginia Cancer Institute, Richmond, Virginia
Conditions: Chronic Myelogenous Leukemia - Chronic Phase
Register for Updates
Cardiac Outcomes With Near-Complete Estrogen Deprivation
NCT05309655
Recruiting
The purpose of this research study is to understand what effect near complete estrogen deprivation (NCED) therapy has on the heart in breast cancer patients. Investigators want to understand if NCED changes how the heart works.
Gender:
Female
Ages:
Between 18 years and 55 years
Trial Updated:
06/06/2024
Locations: Virginia Commonwealth University Massey Cancer Center, Richmond, Virginia
Conditions: Breast Cancer, Triple Negative Breast Cancer, Cardiovascular Complications
Register for Updates
A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children With CAH
NCT05128942
Recruiting
An investigation of the safety and efficacy of tildacerfont in participants with CAH.
Gender:
All
Ages:
2 years and above
Trial Updated:
06/06/2024
Locations: Spruce Study Site, Richmond, Virginia
Conditions: Congenital Adrenal Hyperplasia, 21-OHD
Register for Updates
Genome Transplant Dynamics
NCT02423070
Recruiting
Background: - Some people with advanced heart and lung disease have heart and lung transplants. But the organs are often rejected. When this happens, the organ recipients must have repeated biopsies. These are invasive and expensive. Researchers want to see if a blood test can predict rejection and take the place of biopsies. The test shows how much donor DNA is in a recipient s blood. Objective: - To see if a new blood test can be used instead of biopsies to diagnose rejection after transpla... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
06/06/2024
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Thoracic Organ Transplantation
Register for Updates
Improving Exercise Capacity With a Tailored Physical Activity Intervention
NCT05595577
Recruiting
The purpose of this research is to test whether participating in either a physical activity intervention or a series of educational classes will help to preserve exercise capability, heart function, brain-based activities (like memory), and quality of life. Participants will be randomized to 1 of 2 pathways: First pathway consists of organized health workshops. These workshops are intended to provide information on topics such as proper nutrition, management of stress, sleep practices, and emp... Read More
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
06/06/2024
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Non Hodgkin Lymphoma, Heart; Functional Disturbance, Hodgkin Lymphoma, Quality of Life, Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
Register for Updates
A Study to Evaluate the Efficacy and Safety of RO7434656 in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
NCT05797610
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of RO7434656, a novel Antisense Oligonucleotide (ASO) therapy in participants with primary IgA nephropathy (IgAN) who are at high risk of progressive kidney disease despite optimized supportive care.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/06/2024
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Primary IgA Nephropathy
Register for Updates
Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer
NCT04936230
Recruiting
This phase II trial compares the effect of adding radiation therapy to an immunotherapy drug called pembrolizumab versus pembrolizumab alone in treating patients with urothelial cancer that has spread from where it first started (primary site) to other places in the body (metastatic). The addition of radiation to immunotherapy may shrink the cancer, but it could also cause side effects. Immunotherapy with monoclonal antibodies such as pembrolizumab, may help the body's immune system attack the c... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/06/2024
Locations: VCU Massey Cancer Center at Stony Point, Richmond, Virginia +1 locations
Conditions: Metastatic Urothelial Carcinoma, Platinum-Resistant Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8
Register for Updates
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
NCT05174169
Recruiting
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/05/2024
Locations: Virginia Cancer Institute, Richmond, Virginia +2 locations
Conditions: Stage III Colon Cancer
Register for Updates
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
NCT05006716
Recruiting
Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)
Gender:
All
Ages:
18 years and above
Trial Updated:
06/05/2024
Locations: Virginia Commonwealth University Massey Cancer Center, Richmond, Virginia
Conditions: B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-hodgkin Lymphoma, Waldenström Macroglobulinemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma
Register for Updates
Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)
NCT05291091
Recruiting
A study of sevasemten (EDG-5506) in Becker muscular dystrophy (known as CANYON) and pivotal cohort (known as GRAND CANYON). The EDG-5506-201 CANYON study was expanded to include an additional 120 adult participants in a cohort called GRAND CANYON, that is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of sevasemten in adults with Becker. CANYON is fully enrolled; GRAND CANYON is currently enrolling.
Gender:
Male
Ages:
Between 12 years and 50 years
Trial Updated:
06/05/2024
Locations: Virginia Commonwealth University Health, Richmond, Virginia
Conditions: Becker Muscular Dystrophy
Register for Updates
Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults (ENLIGHTEN 2)
NCT05295459
Recruiting
Multicenter, phase III, randomized, blinded, controlled, parallel group.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/05/2024
Locations: Lyra Investigational Site, Richmond, Virginia
Conditions: Chronic Sinusitis, Chronic Rhinosinusitis (Diagnosis)
Register for Updates
Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
NCT03833154
Recruiting
This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab with SoC SBRT versus placebo with SoC SBRT in patients with unresected clinical Stage I/II lymph node-negative (T1 to T3N0M0) NSCLC. An additional cohort will assess Osimertinib following SBRT in patients with early stage unresected T1 to T3N0M0 NSCLC harbouring an EGFR mutation.
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
06/05/2024
Locations: Research Site, Richmond, Virginia +2 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates